Literature DB >> 3208797

The metabolism and disposition of D-penicillamine in the DA-strain rat.

A E Pilkington1, R H Waring.   

Abstract

Radiolabelled [35S]-D-penicillamine was administered orally to DA-strain rats. After 72 hours approximately 65% of the dose was excreted with no significant differences between male and female animals. The major urinary product was inorganic sulphate with small amounts of D-penicillamine. Penicillamine disulphide, penicillamine-cysteine, S-methyl penicillamine and N-acetyl penicillamine were also found as metabolites. The female rat excreted significantly less sulphate (P less than 0.1) and more penicillamine disulphide (P less than 0.01) than the male. The residual radioactivity was found in the carcass, with slight concentration in the gut, skin, kidney, bladder and liver.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208797     DOI: 10.1007/BF03191310

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  [Pharmacokinetic studies after oral application of radioactively labelled D-penicillamine].

Authors:  K Patzschke; L Wegner; H Kaller; F A Horster
Journal:  Z Rheumatol       Date:  1977 Mar-Apr       Impact factor: 1.372

2.  The acetylation of S-alkylcysteines by the rat.

Authors:  E A Barnsley; N A Eskin; S P James; R H Waring
Journal:  Biochem Pharmacol       Date:  1969-10       Impact factor: 5.858

3.  Studies on D-penicillamine metabolism in cystinuria and rheumatoid arthritis: isolation of S-methyl-D-penicillamine.

Authors:  D Perrett; W Sneddon; A D Stephens
Journal:  Biochem Pharmacol       Date:  1976-02-01       Impact factor: 5.858

4.  Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.

Authors:  S G Al-Dabbagh; J R Idle; R L Smith
Journal:  J Pharm Pharmacol       Date:  1981-03       Impact factor: 3.765

5.  Toxicity of penicillamine. A serious limitation to therapy in rheumatoid arthritis.

Authors:  P B Halverson; F Kozin; G C Bernhard; A L Goldman
Journal:  JAMA       Date:  1978-10-20       Impact factor: 56.272

6.  [Pharmacokinetic and metabolism of D- and L-penicillamine. 2. Distribution of D- and L-penicillamine-14C in the rat organism after oral administration].

Authors:  A Ruiz-Torres
Journal:  Arzneimittelforschung       Date:  1974-07

7.  D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3.

Authors:  P Emery; G S Panayi; G Huston; K I Welsh; S C Mitchell; R R Shah; J R Idle; R L Smith; R H Waring
Journal:  J Rheumatol       Date:  1984-10       Impact factor: 4.666

8.  Specific incorporation of penicillamine into the epidermis of mice: an autoradiographic study.

Authors:  V Ruocco; E De Angelis; M De Luca; M Pisani; G Prota
Journal:  Br J Dermatol       Date:  1983-04       Impact factor: 9.302

9.  CYSTINURIA: EFFECT OF D-PENICILLAMINE ON PLASMA AND URINARY CYSTINE CONCENTRATIONS.

Authors:  J C CRAWHALL; C J THOMPSON
Journal:  Science       Date:  1965-03-19       Impact factor: 47.728

10.  Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole.

Authors:  Z Husain; L A Runge
Journal:  J Rheumatol       Date:  1980 Nov-Dec       Impact factor: 4.666

View more
  1 in total

1.  Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo.

Authors:  Rana Rais; Randall Hoover; Krystyna Wozniak; Michelle A Rudek; Takashi Tsukamoto; Jesse Alt; Camilo Rojas; Barbara S Slusher
Journal:  Drug Metab Dispos       Date:  2012-09-04       Impact factor: 3.922

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.